Galectin-3 in Predicting Mortality of Heart Failure: A Systematic Review and Meta-Analysis

Heart Surg Forum. 2021 Mar 30;24(2):E327-E332. doi: 10.1532/hsf.3547.

Abstract

Background: In recent years, galectin-3, an inflammatory marker, has been demonstrated to be closely related to cardiac fibrosis and heart failure. The purpose of this systematic review and meta-analysis is to define galectin-3 in predicting mortality of heart failure.

Methods: PubMed, Embase, and the Cochrane Library were searched. A total of 1540 studies were identified, and of these studies, 19 involving 9217 patients were included in our meta-analysis.

Results: The diagnostic hazard ratios of galectin-3 in predicting mortality in chronic heart failure patients was 1.13 (95% CI,:1.07-1.21 ) and 2.17 (95% CI:1.27-3.08) in acute heart failure (HF) patients.

Conclusions: Our meta-analysis shows that elevated levels of galectin-3 are associated with higher mortality in both acute and chronic heart failure patients.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Biomarkers / blood
  • Blood Proteins
  • Galectins / blood*
  • Global Health
  • Heart Failure / blood*
  • Heart Failure / mortality
  • Humans
  • Prognosis
  • Risk Factors
  • Survival Rate / trends

Substances

  • Biomarkers
  • Blood Proteins
  • Galectins
  • LGALS3 protein, human